Comparison of CAR T-cell and bispecific antibody as third-line or later-line treatments for multiple myeloma: a meta-analysis.

J Immunother Cancer · 2024 · PMC11574411 · PMID 39551604

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The cilta-cel group showed a trend toward higher efficacy, offering valuable insights for clinicians when selecting CAR-T products.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.